Glucose Monitoring

A presentation at the fall live meeting of the ACO & Emerging Healthcare Delivery Coalition® focused on the clinical and economic consequences of not meeting glycemic goals in patients with type 2 diabetes.

Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes.

Patients with schizophrenia are at high risk of developing diabetes, particularly due to the effects of antipsychotic medications, but the results of a recently published trial indicate liraglutide can help improve glucose tolerance and body weight in prediabetic patients.

Prior data had indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors could be linked to diabetic ketoacidosis, a serious complication of diabetes.

A new study published in Diabetes Care investigates ways to prevent driving accidents among patients with type 1 diabetes, who may be at higher risk of having such mishaps.

Research presented this week at the 99th annual meeting of the Endocrine Society suggested that people with type 2 diabetes who worked overnight shifts tend to have poorer control over their blood sugar levels than those who worked during the day or were unemployed.

With new technologies that allow insulin to be delivered much more easily and at a targeted speed, diabetes treatment is less likely to interfere with patients’ lives, explained Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

A new study published in Annals of Internal Medicine has observed encouraging results from a program that implemented a virtual glucose management system for hospital inpatients.

Recent advances in insulin formulations and innovative drug classes have made it easier than ever to manage diabetic patients’ glucose levels, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

Toxic air has long been suspected as a contributor to diabetes and obesity, but this study is the first to find a direct link.

Patients have a number of concerns about insulin, including pain from injections and interference with their activities, said Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America. However, clinicians must play an important role in explaining to patients how recent advances have made insulin delivery simpler and more convenient.

Researchers considered finding a diabetes drug that also produced a cardiovascular benefit to be a "holy grail."

A point of care medication delivery system improves medication adherence to cardiovascular medications without increasing costs.

The warnings will address 2 issues: the risk of too much acid in the blood and severe urinary tract infections.

The health benefits for participants of the Complete Health Improvement Program ("CHIP"), a lifestyle medicine program, are present regardless of the program tuition payment source.

The technique deploys several strategies to reduce cancer risk. It is being evaluated in mouse models but researchers are already looking ahead to human studies.